DFTX
Definium Therapeutics, Inc.
1W: +1.8%
1M: +6.5%
YTD: +34.8%
$18.40
-0.26 (-1.39%)
After Hours: $18.54 (+0.14, +0.73%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$0.9M
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.8B
52W Range12.882-19.63
Volume1,538,065
Avg Volume2,525,520
Beta2.68
Dividend—
Analyst Ratings
Company Info
CEORobert Barrow
Employees74
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2026-01-06
Websitedefiniumtx.com
One World Trade Center
New York, NY 10007
US
New York, NY 10007
US
212 220 6633
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Latest News
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names
-inc-logo-1200x675.jpg?v=20240515130629){kind=logo}
Ally Bridge Group NY LLC Sells 364,728 Shares of Definium Therapeutics, Inc. $DFTX
Equities Analysts Set Expectations for DFTX Q1 Earnings
Definium (DFTX) Q4 2025 Earnings Call Transcript
Definium Therapeutics targets three pivotal Phase III readouts in 2026 as enrollment advances and cash runway extends into 2028
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Sullivan Mark | A-Award | 125,000 | — | 2026-02-03 |
| Karlin Daniel | A-Award | 150,000 | — | 2026-02-03 |
| Barrow Robert | A-Award | 320,000 | — | 2026-02-03 |
| Wiley Matthew T. | A-Award | 115,000 | — | 2026-02-03 |
| Roberts Brandi | A-Award | 150,000 | — | 2026-02-03 |